Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
74 hedge funds and large institutions have $453M invested in Aimmune Therapeutics in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 8 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 12
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
42% more capital invested
Capital invested by funds: $319M → $453M (+$134M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
0% more funds holding
Funds holding: 74 → 74 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$9.45M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.54M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$2.62M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.44M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$12.8M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$688K |
| 3 |
D.E. Shaw & Co
New York
|
-$215K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$207K |
| 5 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$154K |
AIMT Hedge Fund Activity: Q3 2016 in Review
74 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q3 2016, worth a combined $453M — up 42% from $319M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AIMT positions and 8 closed out — a net gain of 1 holder — while 36 added to existing stakes and 12 trimmed.
The largest buyer was Foresite Capital Management III, adding an estimated $9.45M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $12.8M sold.
- 74 institutional investors held Aimmune Therapeutics (AIMT) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $453M of Aimmune Therapeutics stock for Q3 2016, up 42% quarter-over-quarter.
- 9 funds opened new Aimmune Therapeutics positions in Q3 2016 and 8 closed out, a net change of +1 holder.
- The largest Aimmune Therapeutics buyer in Q3 2016 was Foresite Capital Management III, an estimated $9.45M added.
- The largest Aimmune Therapeutics seller in Q3 2016 was Pictet Asset Management (UK), an estimated $12.8M sold.
Based on aggregated 13F filings for Q3 2016.